Mr. Novik is a Director of PROLOR Biotech and its President.
Mr. Novik previously served as Chief Operating Officer and Head of Strategic Planning of THCG, a technology and life sciences investment company.
THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds.
THCG's own portfolio included several life sciences and medical devices companies.
Prior to his position at THCG, Mr. Novik served as Chief Operating Officer and Chairman of Strategy Committee of RogersCasey, an investment advisory company serving Fortune 500 companies such as DuPont, Kodak, General Electric and others. Mr. Novik is the co-founder and Chairman of the board of Stentomics Inc., a drug-eluting stent technology company developing next-generation, polymer-free drug-eluting stent solutions.
Mr. Novik served for seven years in the Israeli Defense Forces, and received his M.B.A, with Distinction, from Cornell University.